Yuki Kuwabara
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yuki Kuwabara has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Siamak Salavatian
University of Pittsburgh
4 shared publications - Aman Mahajan
Department of Anesthesiology and Perioperative Medicine, University of Pittsburgh, University of Pittsburgh Medical Center (UPMC), Pittsburgh, PA 15260, USA
2 shared publications - Abigail Hellman
Department of Anesthesiology and Perioperative Medicine, University of Pittsburgh, Pittsburgh, PA 15261, USA
1 shared publication - Ali Bahrami Rad
Emory University School of Medicine
1 shared publication - Benjamin Wong
Department of Anesthesiology and Perioperative Medicine, University of Pittsburgh, Pittsburgh, PA 15261, USA
1 shared publication - Bradley K. Taylor
Department of Anesthesiology and Perioperative Medicine, Department of Pharmacology, Pittsburgh Center for Pain Research, and Pittsburgh Project to End Opioid Misuse, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
1 shared publication
Latest Publications
- Open Access
- 26 September 2025
- Published by Cambridge University Press (CUP) in Cambridge Open Engage
Towards Closed-Loop Neuromodulation: AI Prediction of Ventricular Tachyarrhythmias from Multimodal Biosignals in a Porcine Ischemia Model
Myocardial ischemia hyperactivates cardiac sensory neurons, disrupting autonomic balance through excessive sympathetic activity and predisposing the heart to fatal ventricular tachyarrhythmias (VTs). Neuromodulation therapies, including spinal cord stimulation, can suppress ischemia-induced sympathoexcitation. However, open-loop neuromodulation techniques lack adaptive control, leading to suboptimal precision, reduced long-term efficacy, and potential side effects. Closed-loop systems require reliable biofeedback to anticipate autonomic dysfunction and arrhythmic risk. In this study, we evaluate whether epicardial mapping, surface ECG, and arterial blood pressure can provide robust biofeedback signals for predicting VT incidence. Anesthetized Yorkshire pigs (n=12) were subjected to 1 hour of left anterior descending coronary artery ischemia, during which we recorded epicardial electrograms, surface ECG, and blood pressure. To confirm the increased sympathoexcitation and arrhythmogenicity during LAD ischemia, we measured the activation recovery interval, a surrogate for action potential duration, and the dispersion of repolarization. Additionally, we assessed the arrhythmia incidence by identifying the VT episodes. An AI method was then used to assess whether VT could be predicted using 20-second data segments leading to VT. During LAD ischemia, we observed shortened ARIs, increased DORs, and elevated arrhythmia scores, confirming the presence of sympathoexcitation and arrhythmogenicity. The AI model demonstrated a sensitivity of 0.774 and a specificity of 0.770, with a positive predictive value of 0.632 and a negative predictive value of 0.870. This study suggests that combining epicardial electrograms, surface ECG, and blood pressure may provide reliable inputs for an AI-assisted closed-loop system capable of predicting VT onset and triggering neuromodulation therapy before arrhythmia develops.
- 26 September 2025
- Published by Cambridge University Press (CUP) in Cambridge Open Engage
Open AccessTowards Closed-Loop Neuromodulation: AI Prediction of Ventricular Tachyarrhythmias from Multimodal Biosignals in a Porcine Ischemia Model
Myocardial ischemia hyperactivates cardiac sensory neurons, disrupting autonomic balance through excessive sympathetic activity and predisposing the heart to fatal ventricular tachyarrhythmias (VTs). Neuromodulation therapies, including spinal cord stimulation, can suppress ischemia-induced sympathoexcitation. However, open-loop neuromodulation techniques lack adaptive control, leading to suboptimal precision, reduced long-term efficacy, and potential side effects. Closed-loop systems require reliable biofeedback to anticipate autonomic dysfunction and arrhythmic risk. In this study, we evaluate whether epicardial mapping, surface ECG, and arterial blood pressure can provide robust biofeedback signals for predicting VT incidence. Anesthetized Yorkshire pigs (n=12) were subjected to 1 hour of left anterior descending coronary artery ischemia, during which we recorded epicardial electrograms, surface ECG, and blood pressure. To confirm the increased sympathoexcitation and arrhythmogenicity during LAD ischemia, we measured the activation recovery interval, a surrogate for action potential duration, and the dispersion of repolarization. Additionally, we assessed the arrhythmia incidence by identifying the VT episodes. An AI method was then used to assess whether VT could be predicted using 20-second data segments leading to VT. During LAD ischemia, we observed shortened ARIs, increased DORs, and elevated arrhythmia scores, confirming the presence of sympathoexcitation and arrhythmogenicity. The AI model demonstrated a sensitivity of 0.774 and a specificity of 0.770, with a positive predictive value of 0.632 and a negative predictive value of 0.870. This study suggests that combining epicardial electrograms, surface ECG, and blood pressure may provide reliable inputs for an AI-assisted closed-loop system capable of predicting VT onset and triggering neuromodulation therapy before arrhythmia develops.
- Open Access
- 21 July 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (7) , 1776
Neuromodulation of the Cardiac Autonomic Nervous System for Arrhythmia Treatment
This review explores current and emerging neuromodulation techniques targeting the cardiac autonomic nervous system for the treatment and prevention of atrial and ventricular arrhythmias. Arrhythmias remain a significant cause of morbidity and mortality, with the autonomic nervous system playing a crucial role in arrhythmogenesis. Interventions span surgical, pharmacological, and bioelectronic methods. We discuss the range of neuromodulation methods targeting the stellate ganglion, the spinal region, the parasympathetic system, and other promising methods. These include stellate ganglion block, stellate ganglion ablation, cardiac sympathetic denervation, subcutaneous electrical stimulation, thoracic epidural anesthesia, spinal cord stimulation, dorsal root ganglion stimulation, vagus nerve stimulation, baroreflex activation therapy, carotid body ablation, renal denervation, ganglionated plexi ablation, acupuncture, and transcutaneous magnetic stimulation. Both preclinical and clinical studies are presented as evidence for arrhythmia management.
- 21 July 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (7) , 1776
Open AccessNeuromodulation of the Cardiac Autonomic Nervous System for Arrhythmia Treatment
This review explores current and emerging neuromodulation techniques targeting the cardiac autonomic nervous system for the treatment and prevention of atrial and ventricular arrhythmias. Arrhythmias remain a significant cause of morbidity and mortality, with the autonomic nervous system playing a crucial role in arrhythmogenesis. Interventions span surgical, pharmacological, and bioelectronic methods. We discuss the range of neuromodulation methods targeting the stellate ganglion, the spinal region, the parasympathetic system, and other promising methods. These include stellate ganglion block, stellate ganglion ablation, cardiac sympathetic denervation, subcutaneous electrical stimulation, thoracic epidural anesthesia, spinal cord stimulation, dorsal root ganglion stimulation, vagus nerve stimulation, baroreflex activation therapy, carotid body ablation, renal denervation, ganglionated plexi ablation, acupuncture, and transcutaneous magnetic stimulation. Both preclinical and clinical studies are presented as evidence for arrhythmia management.
- 1 December 2023
- Published by American Physiological Society in American Journal of Physiology-Heart and Circulatory Physiology
- Vol. 325 (6) , H1304-H1317
Real-time in vivo thoracic spinal glutamate sensing during myocardial ischemia
In this study, we have developed a new flexible sensing probe to perform an in vivo measurement of spinal glutamate signaling in a large animal model. Our initial investigations involved precise testing of this probe in both in vitro and ex vivo environments. We accurately assessed the sensitivity and specificity of our glutamate-sensing probe and demonstrated its performance. We also evaluated the performance of our developed flexible probe during the insertion and compared it with the stiff probe during animal movement. Subsequently, we used this innovative technique to monitor the spinal glutamate signaling during myocardial ischemia and reperfusion that can cause fatal ventricular arrhythmias. We showed that glutamate concentration increases during the myocardial ischemia, persists during the reperfusion, and is associated with sympathoexcitation and increases in myocardial substrate excitability.
- 1 December 2023
- Published by American Physiological Society in American Journal of Physiology-Heart and Circulatory Physiology
- Vol. 325 (6) , H1304-H1317
Real-time in vivo thoracic spinal glutamate sensing during myocardial ischemia
In this study, we have developed a new flexible sensing probe to perform an in vivo measurement of spinal glutamate signaling in a large animal model. Our initial investigations involved precise testing of this probe in both in vitro and ex vivo environments. We accurately assessed the sensitivity and specificity of our glutamate-sensing probe and demonstrated its performance. We also evaluated the performance of our developed flexible probe during the insertion and compared it with the stiff probe during animal movement. Subsequently, we used this innovative technique to monitor the spinal glutamate signaling during myocardial ischemia and reperfusion that can cause fatal ventricular arrhythmias. We showed that glutamate concentration increases during the myocardial ischemia, persists during the reperfusion, and is associated with sympathoexcitation and increases in myocardial substrate excitability.
- Open Access
- 7 October 2023
- Published by MDPI AG in Biomedicines
- Vol. 11 (10) , 2720
Thoracic Dorsal Root Ganglion Application of Resiniferatoxin Reduces Myocardial Ischemia-Induced Ventricular Arrhythmias
Background: A myocardial ischemia/reperfusion (IR) injury activates the transient receptor potential vanilloid 1 (TRPV1) dorsal root ganglion (DRG) neurons. The activation of TRPV1 DRG neurons triggers the spinal dorsal horn and the sympathetic preganglionic neurons in the spinal intermediolateral column, which results in sympathoexcitation. In this study, we hypothesize that the selective epidural administration of resiniferatoxin (RTX) to DRGs may provide cardioprotection against ventricular arrhythmias by inhibiting afferent neurotransmission during IR injury. Methods: Yorkshire pigs (n = 21) were assigned to either the sham, IR, or IR + RTX group. A laminectomy and sternotomy were performed on the anesthetized animals to expose the left T2–T4 spinal dorsal root and the heart for IR intervention, respectively. RTX (50 μg) was administered to the DRGs in the IR + RTX group. The activation recovery interval (ARI) was measured as a surrogate for the action potential duration (APD). Arrhythmia risk was investigated by assessing the dispersion of repolarization (DOR), a marker of arrhythmogenicity, and measuring the arrhythmia score and the number of non-sustained ventricular tachycardias (VTs). TRPV1 and calcitonin gene-related peptide (CGRP) expressions in DRGs and CGRP expression in the spinal cord were assessed using immunohistochemistry. Results: The RTX mitigated IR-induced ARI shortening (−105 ms ± 13 ms in IR vs. −65 ms ± 11 ms in IR + RTX, p = 0.028) and DOR augmentation (7093 ms2 ± 701 ms2 in IR vs. 3788 ms2 ± 1161 ms2 in IR + RTX, p = 0.020). The arrhythmia score and VT episodes during an IR were decreased by RTX (arrhythmia score: 8.01 ± 1.44 in IR vs. 3.70 ± 0.81 in IR + RTX, p = 0.037. number of VT episodes: 12.00 ± 3.29 in IR vs. 0.57 ± 0.3 in IR + RTX, p = 0.002). The CGRP expression in the DRGs and spinal cord was decreased by RTX (DRGs: 6.8% ± 1.3% in IR vs. 0.6% ± 0.2% in IR + RTX, p < 0.001. Spinal cord: 12.0% ± 2.6% in IR vs. 4.5% ± 0.8% in IR + RTX, p = 0.047). Conclusions: The administration of RTX locally to thoracic DRGs reduces ventricular arrhythmia in a porcine model of IR, likely by inhibiting spinal afferent hyperactivity in the cardio–spinal sympathetic pathways.
- 7 October 2023
- Published by MDPI AG in Biomedicines
- Vol. 11 (10) , 2720
Open AccessThoracic Dorsal Root Ganglion Application of Resiniferatoxin Reduces Myocardial Ischemia-Induced Ventricular Arrhythmias
Background: A myocardial ischemia/reperfusion (IR) injury activates the transient receptor potential vanilloid 1 (TRPV1) dorsal root ganglion (DRG) neurons. The activation of TRPV1 DRG neurons triggers the spinal dorsal horn and the sympathetic preganglionic neurons in the spinal intermediolateral column, which results in sympathoexcitation. In this study, we hypothesize that the selective epidural administration of resiniferatoxin (RTX) to DRGs may provide cardioprotection against ventricular arrhythmias by inhibiting afferent neurotransmission during IR injury. Methods: Yorkshire pigs (n = 21) were assigned to either the sham, IR, or IR + RTX group. A laminectomy and sternotomy were performed on the anesthetized animals to expose the left T2–T4 spinal dorsal root and the heart for IR intervention, respectively. RTX (50 μg) was administered to the DRGs in the IR + RTX group. The activation recovery interval (ARI) was measured as a surrogate for the action potential duration (APD). Arrhythmia risk was investigated by assessing the dispersion of repolarization (DOR), a marker of arrhythmogenicity, and measuring the arrhythmia score and the number of non-sustained ventricular tachycardias (VTs). TRPV1 and calcitonin gene-related peptide (CGRP) expressions in DRGs and CGRP expression in the spinal cord were assessed using immunohistochemistry. Results: The RTX mitigated IR-induced ARI shortening (−105 ms ± 13 ms in IR vs. −65 ms ± 11 ms in IR + RTX, p = 0.028) and DOR augmentation (7093 ms2 ± 701 ms2 in IR vs. 3788 ms2 ± 1161 ms2 in IR + RTX, p = 0.020). The arrhythmia score and VT episodes during an IR were decreased by RTX (arrhythmia score: 8.01 ± 1.44 in IR vs. 3.70 ± 0.81 in IR + RTX, p = 0.037. number of VT episodes: 12.00 ± 3.29 in IR vs. 0.57 ± 0.3 in IR + RTX, p = 0.002). The CGRP expression in the DRGs and spinal cord was decreased by RTX (DRGs: 6.8% ± 1.3% in IR vs. 0.6% ± 0.2% in IR + RTX, p < 0.001. Spinal cord: 12.0% ± 2.6% in IR vs. 4.5% ± 0.8% in IR + RTX, p = 0.047). Conclusions: The administration of RTX locally to thoracic DRGs reduces ventricular arrhythmia in a porcine model of IR, likely by inhibiting spinal afferent hyperactivity in the cardio–spinal sympathetic pathways.
- Open Access
- 2 May 2023
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 18 (5) , e0285120
Propofol anesthesia decreases the incidence of new-onset postoperative atrial fibrillation compared to desflurane in patients undergoing video-assisted thoracoscopic surgery: A retrospective single-center study
Background: Postoperative atrial fibrillation (POAF) increases postoperative morbidity, mortality, and length of hospital stay. Propofol is reported to modulate atrial electrophysiology and the cardiac autonomic nervous system. Therefore, we retrospectively examined whether propofol suppresses POAF in patients undergoing video-assisted thoracoscopic surgery (VATS) compared to desflurane. Methods: We retrospectively recruited adult patients who underwent VATS during the period from January 2011 to May 2018 in an academic university hospital. Between continuous propofol and desflurane administration during anesthetic maintenance, we investigated the incidence of new-onset POAF (within 48 hours after surgery) before and after propensity score matching. Results: Of the 482 patients, 344 received propofol, and 138 received desflurane during anesthetic maintenance. The incidence of POAF in the propofol group was less than that in the desflurane group (4 [1.2%] vs. 8 patients [5.8%], odds ratio [OR]; 0.161, 95% confidence interval (CI), 0.040–0.653, p = 0.011) in the present study population. After adjustment for propensity score matching (n = 254, n = 127 each group), the incidence of POAF was still less in propofol group than desflurane group (1 [0.8%] vs. 8 patients [6.3%], OR; 0.068, 95% CI: 0.007–0.626, p = 0.018). Conclusions: These retrospective data suggest propofol anesthesia significantly inhibits POAF compared to desflurane anesthesia in patients undergoing VATS. Further prospective studies are needed to elucidate the mechanism of propofol on the inhibition of POAF.
- 2 May 2023
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 18 (5) , e0285120
Open AccessPropofol anesthesia decreases the incidence of new-onset postoperative atrial fibrillation compared to desflurane in patients undergoing video-assisted thoracoscopic surgery: A retrospective single-center study
Background: Postoperative atrial fibrillation (POAF) increases postoperative morbidity, mortality, and length of hospital stay. Propofol is reported to modulate atrial electrophysiology and the cardiac autonomic nervous system. Therefore, we retrospectively examined whether propofol suppresses POAF in patients undergoing video-assisted thoracoscopic surgery (VATS) compared to desflurane. Methods: We retrospectively recruited adult patients who underwent VATS during the period from January 2011 to May 2018 in an academic university hospital. Between continuous propofol and desflurane administration during anesthetic maintenance, we investigated the incidence of new-onset POAF (within 48 hours after surgery) before and after propensity score matching. Results: Of the 482 patients, 344 received propofol, and 138 received desflurane during anesthetic maintenance. The incidence of POAF in the propofol group was less than that in the desflurane group (4 [1.2%] vs. 8 patients [5.8%], odds ratio [OR]; 0.161, 95% confidence interval (CI), 0.040–0.653, p = 0.011) in the present study population. After adjustment for propensity score matching (n = 254, n = 127 each group), the incidence of POAF was still less in propofol group than desflurane group (1 [0.8%] vs. 8 patients [6.3%], OR; 0.068, 95% CI: 0.007–0.626, p = 0.018). Conclusions: These retrospective data suggest propofol anesthesia significantly inhibits POAF compared to desflurane anesthesia in patients undergoing VATS. Further prospective studies are needed to elucidate the mechanism of propofol on the inhibition of POAF.